美国抗糖尿病药物使用长期趋势:新诊断2型糖尿病患者的真实世界证据
研究基于美国Centricity电子病历,纳入1,023,340例新起始抗糖尿病药物的2型糖尿病患者,分析2005至2016年用药模式。结果显示二甲双胍一线使用增加而磺脲类减少,但磺脲类仍是二线最常用药物;多数患者在HbA1c 8.4%时才起始二线治疗。与磺脲类相比,肠促胰岛素类治疗与胰岛素起始需求的小幅延迟相关。
要点
- 2005至2016年,二甲双胍一线使用从60%增至77%,磺脲类从20%降至8%。
- 二线治疗中磺脲类使用从60%降至46%,但仍是最常用二线药物。
- 二线DPP-4i和GLP-1RA组至胰岛素起始的限制平均时间分别为7.1年和6.6年,长于磺脲类的6.3年(P<0.05)。
核心结论
- 多数患者在HbA1c升高时起始二线治疗,不同抗糖尿病药物类别的临床特征高度异质。
- 尽管有新疗法出现,磺脲类仍是最常用的二线药物,且磺脲类和胰岛素的强化治疗率随时间保持稳定。
- 与磺脲类相比,肠促胰岛素类治疗与治疗强化需求的小幅延迟相关。
研究设计与样本
- 从美国Centricity电子病历中选取年龄18-80岁、起始任何抗糖尿病药物的2型糖尿病患者(n=1,023,340)。
- 识别在二甲双胍一线治疗后起始二线抗糖尿病药物的患者(亚队列1,n=357,482),并进一步探索三线治疗选择。
主要发现
- 2005至2016年,一线二甲双胍使用从60%增至77%,磺脲类从20%降至8%。
- 二甲双胍治疗后平均随访3.4年期间,48%的患者在平均HbA1c 8.4%时起始第二种抗糖尿病药物。
- 亚队列1中,二线磺脲类使用从60%降至46%,但仍是最常用的二线选择;胰岛素使用从7%增至17%,DPP-4i从0.4%增至21%。
- 过去10年,胰岛素和磺脲类的强化治疗率未下降。
- 至胰岛素起始的限制平均时间:二线DPP-4i组7.1年,GLP-1RA组6.6年,磺脲类组6.3年(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OJBECTIVE: To explore temporal trends in antidiabetes drug (ADD) prescribing and intensification patterns, along with glycemic levels and comorbidities, and possible benefits of novel ADDs in delaying the need for insulin initiation in patients diagnosed with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes aged 18-80 years, who initiated any ADD, were selected (n = 1,023,340) from the U.S. Centricity Electronic Medical Records. Those who initiated second-line ADD after first-line metformin were identified (subcohort 1, n = 357,482); the third-line therapy choices were further explored. RESULTS: From 2005 to 2016, first-line use increased for metformin (60-77%) and decreased for sulfonylureas (20-8%). During a mean follow-up of 3.4 years post metformin, 48% initiated a second ADD at a mean HbA1c of 8.4%. In subcohort 1, although sulfonylurea usage as second-line treatment decreased (60-46%), it remained the most popular second ADD choice. Use increased for insulin (7-17%) and dipeptidyl peptidase-4 inhibitors (DPP-4i) (0.4-21%). The rates of intensification with insulin and sulfonylureas did not decline over the last 10 years. The restricted mean time to insulin initiation was marginally longer in second-line DPP-4i (7.1 years) and in the glucagon-like peptide 1 receptor agonist group (6.6 years) compared with sulfonylurea (6.3 years, P < 0.05). CONCLUSIONS: Most patients initiate second-line therapy at elevated HbA1c levels, with highly heterogeneous clinical characteristics across ADD classes. Despite the introduction of newer therapies, sulfonylureas remained the most popular second-line agent, and the rates of intensification with sulfonylureas and insulin remained consistent over time. The incretin-based therapies were associated with a small delay in the need for therapy intensification compared with sulfonylureas.
引用
- Montvida O, Shaw J, Atherton JJ, et al. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2017. PMID: 29109299. doi:10.2337/dc17-1414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。